Featured Research

from universities, journals, and other organizations

Policy changes in elective delivery successful

Date:
February 11, 2013
Source:
Society for Maternal-Fetal Medicine
Summary:
Changes in elective delivery policy successful in reducing elective deliveries prior to 39 weeks.

In a study to be presented on February 14 at the Society for Maternal-Fetal Medicine's annual meeting, The Pregnancy Meeting ™, in San Francisco, California, researchers will present data showing changes in elective delivery policy have been successful in reducing elective deliveries prior to 39 weeks.

Due to the troubling trend of elective delivery and induction, significant attention has been paid to the neonatal benefits of reducing elective deliveries before 39 weeks, both on the national and institutional level. Elective delivery or induction before 39 weeks can lead to bad outcomes for infants including feeding problems, trouble maintaining temperature, having to spend time in the neonatal intensive care unit, and can even put the infant at risk of death.

Studying singleton births at tertiary care centers from 2006 -- 2011, researchers at the Brigham and Woman's Hospital in Boston, Ma. found an overall decrease in the proportion of term deliveries that occurred between 37-38 weeks.

"We found a significant reduction in both early elective inductions and early elective cesareans," said Sarah Little, of Brigham and Women's Hospital. "We even found a decrease in inductions for indications considered non-elective."

However, researchers found no significant change in neonatal or maternal morbidity and also found a nonstatistically significant increase in the rate of stillbirths after 37 weeks. Further study on a much larger scale is needed to accurately assess any increased risk from prolonging high risk pregnancies to 39 weeks.

This study was conducted by Sarah Little, Louise Wilkins-Haug, Davis Acker and Chloe Zera of Brigham and Woman's Hospital, Maternal-Fetal Medicine, Boston, Ma.


Story Source:

The above story is based on materials provided by Society for Maternal-Fetal Medicine. Note: Materials may be edited for content and length.


Cite This Page:

Society for Maternal-Fetal Medicine. "Policy changes in elective delivery successful." ScienceDaily. ScienceDaily, 11 February 2013. <www.sciencedaily.com/releases/2013/02/130211102213.htm>.
Society for Maternal-Fetal Medicine. (2013, February 11). Policy changes in elective delivery successful. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2013/02/130211102213.htm
Society for Maternal-Fetal Medicine. "Policy changes in elective delivery successful." ScienceDaily. www.sciencedaily.com/releases/2013/02/130211102213.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins